PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Drimanial and polygodial exhibited antinociceptive action against acetic acid-induced pain in mice [PMID:11336250, PMID:9849632]
Bark ethyl acetate extract and sesquiterpenes (drimenol, isordrimenone, polygodial) significantly reduced cell viability and induced apoptosis in human melanoma cells [PMID:30935903]
Total bark extract and isodrimeninol inhibited foam cell formation in THP-1 derived macrophages [PMID:33152471]
Drimenol, isodrimeninol, and polygodial reduced monocyte adhesion to stimulated human endothelial cells [PMID:32987110]
Isodrimenin and drimenol were active against the trypomastigote form of T. cruzi [PMID:23923616]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 40537018 (2026) — Neuronal ion channel modulation by Drimys winteri compounds: Opening a new chemical space to neuropharmacology. · Neural regeneration research
- 2.PMID: 38666047 (2024) — Biological activity of the essential oil of Drimys winteri. · Frontiers in chemistry
- 3.PMID: 33234091 (2021) — Ethnopharmacology, Phytochemistry and Biological Activities of Native Chilean Plants. · Current pharmaceutical design
- 4.PMID: 33152471 (2020) — Drimys winteri and isodrimeninol decreased foam cell formation in THP-1 derived macrophages. · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
- 5.PMID: 37444318 (2023)